SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Non-Tech : Attractive opportunities in already announced mergers -- Ignore unavailable to you. Want to Upgrade?


To: D. K. G. who wrote (47)1/13/2012 8:05:38 AM
From: D. K. G.  Read Replies (1) | Respond to of 64
 
.....Gilead nears completion of Pharmasset deal

Gilead Sciences now owns 95 percent of Pharmasset in $11 billion acquisition



Associated Press – Thu, Jan 12, 2012 7:21 AM EST

....

Share0EmailPrint.....Companies:...Pharmasset, Inc.Gilead Sciences Inc. . ..RELATED QUOTES.

.Symbol Price Change

VRUS 136.92 0.00



GILD 44.90 0.00



......



FOSTER CITY, Calif. (AP) -- Gilead Sciences has acquired about 95 percent of the outstanding shares in Pharmasset as it draws closer to closing its $11 billion deal for the drug developer.



Gilead, based in Foster City, Calif., said about 72 million Pharmasset shares have been tendered. Gilead announced in November that it would pay $137 per share in cash for the, a Princeton, N.J. drug developer.



Pharmasset Inc. has three potential hepatitis C treatments in clinical testing, including a candidate labeled PSI-7977 in late-stage testing. Analysts see promise in the drug because doctors may be able prescribe the pill in a combination with other treatments that does not involve interferon, an injection that comes with rough side effects.



Hepatitis C is a virus that can lead to life-threatening liver damage and is the main cause of liver transplants in the United States. Analysts expect it to become a bigger health problem as baby boomers ages.



Gilead Sciences Inc. plans to buy additional shares of Pharmasset directly from the company, which has no drugs on the market. The acquisition is expected to close in the first quarter.



.